Bevacizumab in Treating Patients With Angiosarcoma

DISEASE CHARACTERISTICS: * Histologically confirmed angiosarcoma * Any stage disease * Must be deemed not surgically resectable (complete resection) and/or no other therapeutic modality is known to be curative * No angiosarcoma of a vessel wall * Newly diagnosed or recurrent/refractory disease * No prior tumor-related hemorrhage (any grade) * Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan * No CNS disease, brain metastases, or primary brain tumors PATIENT CHARACTERISTICS: * ECOG performance status of 0 or 1 * Absolute granulocyte count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9 gm/dL (transfusion and epoetin alfa allowed) * Creatinine ≤ 1.5 times upper limit of normal (ULN) * Urine protein:creatinine ratio ≤ 1.0 * Total bilirubin ≤ 1.5 mg/dL * Aspartate aminotransferase \< 5 times ULN * Alkaline phosphatase \< 5 times ULN * PT/INR ≤ 1.5 times ULN * PTT ≤ 1.5 times ULN * Fertile patients must use effective contraception * Ejection fraction \> 49% for patients with prior anthracycline therapy, ischemic cardiac disease, or history of heart failure * No uncontrolled active infection * No uncontrolled high blood pressure (defined as \> 150/100 mm Hg) * No symptomatic congestive heart failure (New York Heart Association class II-IV), unstable angina, cardiac arrhythmia, or myocardial …